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Abstract
Objective: Among older children with sickle cell anemia, leukocyte counts, hemoglobin, and reticulocytosis have previously
been suggested as disease severity markers. Here we explored whether these blood parameters may be useful to predict
early childhood disease severity when tested in early infancy, defined as postnatal ages 60–180 days.
Study Design: Data from fifty-nine subjects who were followed at Children’s National Medical Center’s Sickle Cell Program
for at least three years was retrospectively analyzed. Comparisons were made between white blood cell counts, hemoglobin
and reticulocyte levels measured at ages 60–180 days and the clinical course of sickle cell anemia during infancy and
childhood.
Results: A majority of subjects had demonstrable anemia with increased reticulocytosis. Only increased absolute
reticulocyte levels during early infancy were associated with a significant increase in hospitalization during the first three
years of life. Higher absolute reticulocyte counts were also associated with a markedly shorter time to first hospitalizations
and a four-fold higher cumulative frequency of clinical manifestations over the first three years of life. No significant increase
in white blood cell counts was identified among the infant subjects.
Conclusions: These data suggest that during early infancy, increased reticulocytosis among asymptomatic SCA subjects is
associated with increased severity of disease in childhood.
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Introduction
Although the genetic basis of sickle cell anemia (HbSS, SCA) is
well understood, the clinical phenotype is highly variable and
difficult to predict. [1] Evidence of increased hemolysis begins
during the first year of life as sickle hemoglobin (HbS) replaces
fetal hemoglobin (HbF; a2c2). With time, the consequences of
intracellular HbS polymerization lead to susceptibility to infec-
tions, pain episodes, vascular and multi-organ damage, and
shortened life expectancy. Splenic dysfunction affects over 90%
of subjects before adulthood, [2] therefore antibiotic prophylaxis
[3] is used during infancy to reduce the incidence of life
threatening infection. [4] Patients are also treated with hydroxy-
urea (HU), chronic transfusions, and bone marrow transplanta-
tion, all of which have been shown to improve certain disease
manifestations in children and adults. Monthly blood transfusions
have decreased the stroke risk in SCA subpopulations. [5]
However, because all of these therapies have significant morbidity,
caution is appropriately applied with any such treatment decisions.
[6–8] Ongoing efforts to identify infants and children at high risk
for severe disease are especially relevant for choosing treatment
options.
Ideally, SCA subjects at risk for severe disease should be
identified as complications develop to better target therapeutic
choices and timing. SCA researchers are thus challenged to predict
disease severity before the disease is fully manifested. In the United
States, hemoglobinopathy screening programs permit genetic
diagnosis in newborns with SCA prior to the onset of any disease
manifestations. While approximately 3,000 infants are born in the
US with SCA annually, it is estimated that 250,000 infants are
born annually with SCA in Sub-Saharan Africa. [9] Newborn
screening programs are being implemented in select African
countries that will permit early institution of supportive care
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measures including penicillin prophylaxis. [10] With newborn
screening of infants becoming more widespread in Africa, disease
severity markers that are useful at an early age are a priority for
translational and clinical research. In resource-poor countries,
efforts to target therapy to those children who are at highest risk of
disease complications are especially important. Studies of genetic
markers for the clinical phenotype are advancing, [11] but clinical
markers that are strongly predictive for individual infants with
SCA have not yet been identified.
Previously, a large prospective cohort study was utilized for
identifying disease severity predictors in children with sickle cell
disease. [12–15] However, the severity predictors identified in that
cohort were not fully validated in a subsequent analysis. [16] The
goal of our study is the identification of a globally available SCA
disease severity predictor that is amenable to testing in infants
prior to manifestation of the disease. We sought an inexpensive test
that may be applied to identify infants at higher risk for severe
disease during early childhood.
Materials and Methods
Ethics Statement
Approval for the research protocol and consent documents
pertaining to this study was granted by the Intramural National
Institute of Diabetes and Digestive and Kidney Diseases and the
Children’s National Medical Center Institutional Review Boards.
Written consent from parents and guardians for participants less
than age 18 years and assent, when applicable, were obtained
prior to enrollment.
Subject Eligibility and Enrollment
Retrospective chart review was performed on a subset of HbSS
patients who were part of a longitudinal, observational cohort
study to identify markers of SCA severity. This cohort consists of a
convenience sample of pediatric sickle cell anemia (SCA) patients
through age 21 years who received care at the Children’s National
Medical Center (CNMC) Sickle Cell Program. Only those study
participants who had a steady state complete blood count and
reticulocyte count during early infancy (between the ages of 60 and
180 days) and were born before January 1, 2010 (providing at least
3 years of follow-up) are included in this report. Reticulocyte
number and hemoglobin level (Hb) were measured using a Sysmex
XE 2100 hematology analyzer (Sysmex America, Mundelein, IL).
Analysis of Clinical Outcome Variables
Study outcomes were classified as follows:
1. Painful vaso-occlusive events requiring hospitalization and
intravenous (iv) narcotic pain medication (VOC).
2. Acute chest syndrome (ACS) defined as infiltrate on chest Xray
(CXR) accompanied by three or more of the following: fever
(temperature $38.5 degrees Celsius), cough, wheezing, chest
pain, or tachypnea. [17]
3. Splenic sequestration defined as: splenic enlargement accom-
panied by a hemoglobin 2 g/dL below baseline with evidence
of bone marrow compensation (increased absolute reticulocyte
count). [18]
If subjects had more than one SCA-associated complication
during the first hospitalization, the chief complaint at hospital
presentation (e.g. leg pain or cough) was used as the cause for the
first hospitalization.
Statistical Methods
Statistical analyses were performed using SASH version 9.2. A t-
test was used to compare the absolute reticulocyte count and
hemoglobin of hospitalized and non-hospitalized infants. The four
hospitalization groups (No Hospitalization, ACS, splenic seques-
tration and VOC) were compared using an analysis of variance
with Dunnett’s adjustment for multiple comparisons. Logistic
regression was used to evaluate the relationships between absolute
reticulocyte count and hemoglobin and hospitalization. A Receiv-
er Operator Characteristic (ROC) curve was generated using
logistic regression in order to compare the sensitivity (true positive
rate) and 1-specificity (false positive rate) for absolute reticulocyte
counts versus hemoglobin levels as predictors for probability of
hospitalization. Subjects were divided into four groups using cut-
offs suggested by the ROC curve. A chi-square test for trend was
used to compare the hospitalization rates in the four groups. For
other analyses the groups were analyzed as a categorical variable
rather than a continuous variable. The Kaplan Meier method was
used to estimate the time to first hospitalization and Cox
regression was used to estimate the hazard ratio for subjects in
these four groups. The event rate per person-years in the first 3
years was calculated by dividing the total number of events by the
total years of follow-up up to 3 years and tested using Poisson
regression. Cox regression for repeated events was used to estimate
the cumulative number of hospitalizations in the first three years
for these same four groups. Data are presented as mean 6
standard deviation (SD) unless otherwise indicated. A p value of
,0.05 was considered statistically significant.
Results
Analysis of SCA Severity Markers During Early Infancy
Fifty-nine subjects who were born before January 1, 2010 had a
steady state CBC (including absolute reticulocyte count) between
the ages of 60 and 180 days. Previous analyses [13–15] identified
white blood cell count, hemoglobin, and reticulocytosis in young
children as blood parameters that may be useful for prediction of
future disease severity. Dactylitis was also identified as a disease
severity marker in those studies. In order to determine if these
markers were useful earlier in life, before six months of age, we
compared peripheral blood white blood cell counts, hemoglobin
concentrations, and absolute reticulocyte counts among the 59
patients with those levels measured in healthy infants. [19] None
of the patients in our cohort had dactylitis before the age of 6
months, so this marker was not investigated further. Consistent
with previous reports, the mean absolute reticulocyte count in this
group of SCA infants was 179689 K/uL. As shown in Figure 1A,
there was an upward trend of absolute reticulocyte count in the
older infants, and the absolute reticulocyte count values were
mostly distributed between 100–300 K/uL. Conversely, anemia
(Hb ,9.5) occurred before age 6 months in over two-thirds
(69.5%) of our cohort (Figure 1B). The mean hemoglobin for the
cohort was 8.961.3 g/dL. None of the patients had an elevated
white blood cell count (Figure 1C).
Absolute Reticulocyte Count, Hemoglobin, White Blood
Cell Count and SCA Clinical Events
For this study, hospitalization (or lack thereof) by three years of
age was defined and studied as being indicative of early disease
severity in these 59 subjects. The mean age at first hospitalization
was 17.668.3 months for those subjects who required a
hospitalization in the first 3 years of life. Absolute reticulocyte
counts, hemoglobin levels, and white blood cell counts were
explored for their correlation with hospitalization in the first three
Reticulocytosis and Pediatric Sickle Cell Severity
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years of life. The mean absolute reticulocyte count level
(140663 K/uL) for the 23 subjects who were not hospitalized
was significantly lower than that of the remaining 36 subjects who
required hospitalization during the first three years of life
(204694 K/uL, p = 0.0054), while the mean hemoglobin was
not different between the two groups (Figure 2A, No Hospitaliza-
tion 9.061.1 g/dL vs. Hospitalized group 8.861.4 g/dL,
p = 0.53). The absolute reticulocyte counts of 11 subjects who
were first hospitalized for ACS (mean absolute reticulocyte count
168676 K/uL) was not significantly different than those who
were not hospitalized (p = 0.35). In contrast, the 10 subjects who
were first hospitalized for splenic sequestration and the 15 subjects
first hospitalized for VOC had significantly higher absolute
reticulocyte counts than those who were not hospitalized
(205672 K/uL and 2306114 K/uL respectively, p = 0.042 and
0.0017). After adjusting for multiple comparisons, the absolute
reticulocyte count for the VOC group remained significantly
higher than that for the group with no hospitalizations (p,0.05).
As shown in Figure 2B, the hemoglobin levels of the subjects first
hospitalized for ACS (9.061.3 g/dL), splenic sequestration
(8.461.7 g/dL) and VOC (8.961.2 g/dL) were not significantly
different than those subjects who did not require hospitalization
(p = 0.92, 0.18, and 0.90). White blood cell counts (Figure 2C)
were not significantly different in those patients who required
hospitalization when compared to those who did not. [ACS (mean
white blood cell count 9.0+3.0 K/uL), splenic sequestration (mean
white blood cell count 8.6+2.6 K/uL), VOC (mean white blood
cell count 10.2+2.7 K/uL), no hospitalization (mean white blood
cell count 8.6+2.3 K/uL), p = 0.67, 0.97, 0.08, respectively].
Figure 3 shows the probability of hospitalization versus no
hospitalization as illustrated by ROC curve and Area Under the
Curve (AUC) analyses for absolute reticulocyte count and
hemoglobin. The odds ratios from the logistic regression used to
construct the ROC were 1.74 (95% CI 1.14–2.65) for each 50-unit
change in absolute reticulocyte count and 0.87 (95% CI 0.57–
1.33) for each unit change in Hb. The AUC (0.72; 95% CI 0.59–
0.86; p = 0.0097) demonstrates that increasing reticulocytosis (solid
line) is associated with a significantly higher risk of hospitalization
before age 3 years. An AUC of 0.5 indicates that this discriminator
(absolute reticulocyte count in this instance) is no greater than
chance, while an AUC of 1.0 means it is a perfect discriminator
with 0 false positives and 0 false negatives. [20] All 6 patients who
had an absolute reticulocyte count greater than 280 K/uL were
hospitalized within the first 3 years of life (100% specificity) while
the one patient with an absolute reticulocyte count less than 64 K/
uL was not hospitalized in the first three years of life (100%
sensitivity). The AUC for hemoglobin (0.55, 95% CI 0.41–0.70;
p = 0.52) revealed that hemoglobin was not useful for predicting
hospitalizations in this cohort. Although the AUC for absolute
reticulocyte count (0.72) was higher than the AUC for hemoglobin
(0.55), this difference was not statistically significant (p = 0.12).
Time to First Event and Cumulative Number of Events
The time to first hospitalization and the number of hospital-
izations by age three years were next used as markers of increased
disease severity. The infants were grouped according to their
absolute reticulocyte counts from 60–180 days using the ROC
data shown in Figure 3: absolute reticulocyte count less than
100 K/uL (group 1), absolute reticulocyte count between 100 and
175 K/uL (group 2), absolute reticulocyte count between 176 and
204 K/uL (group 3) and absolute reticulocyte count greater than
or equal to 205 K/uL (group 4). Twenty-nine percent (4/14) of
patients in group 1, 57% (8/14) in group 2, 67% (8/12) in group 3,
and 84% (16/19) in group 4 had an event by age 3 years
(p = 0.0014). We first compared the time to first hospitalization for
these four groups using the Kaplan-Meier method and Cox
Regression. Kaplan-Meier estimates of the time to first hospital-
ization are shown in Figure 4A. The Cox regression hazard ratios,
compared to group 1, were 2.76 (95% CI 0.83–9.20, p = 0.098) for
Figure 1. Absolute Reticulocyte Counts, Hemoglobin and
White Blood Cell distribution during early infancy in a
contemporary, observational SCA cohort. A. Distribution of
absolute reticulocyte count values among 59 subjects ages 60–180
days. B–C. Hemoglobin and White blood cell count distribution in the
same cohort. Shaded area represents the normal range for a 3-month-
old healthy infant. [19] Age in days is shown on the x-axis in each panel.
Correlation coefficients (r) and p- values are shown in each panel. ARC,
Absolute Reticulocyte Count; Hb, hemoglobin; WBC, White Blood Cell
count.
doi:10.1371/journal.pone.0070794.g001
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group 2, 3.45 (95% CI 1.04–11.49, p = 0.044) for group 3, and
6.28 (95% CI 2.08–19.00, p = 0.0011) for group 4.
The total number of clinical events was calculated for each
group and cumulative frequency of events was compared. The
number of events per patient year was increased with increasing
absolute reticulocyte count (5 events, 0.12 events/patient years for
group 1, 12 events (0.31) for group 2, 12 events (0.38) for group 3,
and 41 events (0.81) for group 4, p = ,0.0001). Before three years
of age, the average cumulative number of events was 0.23 for
group 1, 0.60 for group 2, 0.74 for group 3, and 1.44 for group 4,
p = 0.0010 for a Cox regression analysis of recurrent events
(Figure 4B).
Discussion
Data from a previously reported cohort of children with sickle
cell disease identified baseline hemoglobin, white blood cell count
and early dactylitis as predictors of severe SCA. [15] Increasing
reticulocytosis was also associated with a more severe SCA course.
Here we report data collected during early infancy from 59
subjects with the goal of identifying markers of disease severity
during the first three years of life. None of the subjects presented
with dactylitis or leukocytosis before 6 months of age. However,
they manifested more significant anemia and reticulocytosis as
compared to healthy children. Thus, levels of anemia and
reticulocytosis were further analyzed to determine if either could
be used as a very early marker of SCA severity that may be
measured prior to the onset of disease sequelae. The switch from
predominantly fetal to primarily sickle hemoglobin during the first
several months of life leads to anemia with reticulocytosis as a
nearly universal feature of the disease. In the healthy infants,
recovery from the so-called ‘‘physiologic anemia’’ [21] involves the
production of erythrocytes with almost entirely HbA. In infants
with SCA, the erythrocytes containing high levels of HbF
circulating at birth are replaced by erythrocytes with high levels
of HbS and decreased levels of HbF. [22] Once the remaining
fetal cells are cleared from the circulation, anemia develops. [23]
Figure 2. Comparison of absolute reticulocyte counts and
blood hemoglobin and white blood cell levels according to
early hospitalization. A. Steady state absolute reticulocyte count
values measured during early infancy (60–180 days; shown in box and
whiskers format) for subjects with no history of hospitalization (No
Hosp., n = 23) versus subjects who required early hospitalization (before
age three years) for each cause of hospitalization [acute chest syndrome
(ACS, n = 11), splenic sequestration (Splen seq, n = 10) and vaso-
occlusive crisis (VOC, n = 15)]. Equivalent analyses were performed
using hemoglobin levels (Panel B) and white blood cell counts (Panel C).
Unadjusted significance (p values) of differences from the non-
hospitalized group is shown on top of the bars. After adjusting for
multiple comparisons, the absolute reticulocyte count for the VOC
group remained significantly higher than that for the group with no
hospitalizations. ARC, Absolute Reticulocyte Count; Hb, hemoglobin;
WBC, White Blood Cell count.
doi:10.1371/journal.pone.0070794.g002
Figure 3. Receiver operator characteristic (ROC) curve analysis.
ROC curve comparing the patients who required or did not require
hospitalization within the first 3 years of life. Absolute reticulocyte
count (solid line) hemoglobin level (dashed line) values at selected
points (arrows) along the ROC are included. Sensitivity is shown on the
y-axis, and 1-specificity is listed on the x-axis. p values represent
significance of area under the curve. ARC, Absolute Reticulocyte Count;
Hb, hemoglobin; AUC, area under the curve with 95% confidence
intervals (CI).
doi:10.1371/journal.pone.0070794.g003
Reticulocytosis and Pediatric Sickle Cell Severity
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The subsequent reduction in hematocrit leads to increased
production of HbS-containing cells, and tissue hypoxia appears
to remain as a central driver of continued increased reticulocyte
production. A more robust reticulocyte response is predicted in
those SCA infants who are less able to maintain HbF production,
since the physiologic nadir occurs during the fetal-to-adult
hemoglobin transition during human ontogeny. In the absence
of signs or symptoms of clinical disease, the infants identified here
as having increased reticulocyte counts of greater than or equal to
205 K/uL before the age of 180 days were found to have a
significantly increased risk of hospitalization for sickle cell-
associated sequelae before age three years.
The cohort study presented here was limited by its small sample
size and retrospective design, which prevented infants from being
evaluated at standard time points. Additionally, HbF data was not
available for all infants between the ages of 2 and 6 months, which
limited comparison of HbF levels to the SCA severity. None of the
enrolled patients in the contemporary cohort died or had a stroke,
arguably the two most significant consequences of SCA. When
tested in older children, reticulocytosis has also been reported to be
a risk factor for cerebrovascular disease. [24] With improvement
in the supportive care of pediatric SCA patients, death and stroke
are rare events in early childhood. [25] Despite the recognition
that all SCA infants undergo a transition from health to chronic
disease during infancy, there exists a paucity of data concerning
the clinical status of infants during this transition period. No prior
studies identified a predictive marker of sickle cell disease severity
during this early stage of life. The absolute reticulocyte count is an
inexpensive laboratory assay that is currently available and
amenable for clinical assessment of young infants by the global
community. Our data suggest that quantifying absolute reticulo-
cyte counts during early infancy may be useful for predicting
disease severity when the disease is initially manifested in
childhood. However, the limitations of this study suggest that
clinical use of absolute reticulocyte count in early infancy as a
predictor of hospitalizations in the first three years of life should be
currently viewed as tentative until validation is achieved using
larger, more socio-economically and geographically diverse
cohorts of patients.
The findings highlight the importance of newborn screening
programs for infants with SCA since the disease phenotype is
usually delayed in infants and children until after the age of six
months. Further study is needed to determine the potential for
infant reticulocytosis to predict disease severity among older
children or adults, and prospective examinations of reticulocytosis
may explore discrete cohorts including subjects being considered
for HU, transfusion, or transplantation. Since the magnitude of
HbF loss is variable between infants [22,26], detailed studies are
needed to determine if greater loss of HbF during infancy
correlates with higher levels of reticulocytosis. The role of HbF
levels in identifying high-risk infants may also be limited in
developing countries because of difficulties in obtaining these
results, while absolute reticulocyte counts are more readily
obtainable. Since the patient cohort studied here receive their
care from a large clinical center in the United States, ARC from
patient cohorts receiving care in other global locales, including
Africa, should be studied for comparison. Future research should
also include detailed studies of the sickle cell infants’ reticulocyte
biology, hemolysis (bilirubin and LDH levels), splenic function,
and genomics in order to better understand the initial manifes-
tation of the disease. While sickle hemoglobin polymerization
remains the incipient feature of SCA, [27] the host’s erythropoietic
response, including the production and release of reticulocytes
from the marrow that are more adherent to the vascular
endothelium, may play a significant role in determining the
disease phenotype. [28].
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Figure 4. Time to first event and cumulative mean frequency of
events. A. Kaplan Meier curve showing the cumulative proportion of
events by patient groups. The groups were divided by absolute
reticulocyte count based on the ROC curve seen in Figure 3 [absolute
reticulocyte count .205 K/uL (solid line, n = 19, 0.84, 95% CI 0.68–1.01),
absolute reticulocyte count between 176 and 204 K/uL (dotted line,
n = 12, 0.67, 95% CI 0.40–0.93), absolute reticulocyte count between 100
and 175 K/uL (dashed & dotted line, n = 14, 0.57, 95% CI 0.31–0.83),
absolute reticulocyte count ,100 K/uL (dashed line, n = 14, 0.29, 95% CI
0.05–0.52)]. B. Cumulative mean frequency of events curves (cumulative
frequency of hospitalizations on the y-axis vs. age in years on the x-axis)
for the groups described in panel A [absolute reticulocyte count .205
(cumulative mean frequency of events 2.28, 95% CI 1.49–3.49), absolute
reticulocyte count 176–204 (cumulative mean frequency of events 1.17,
95% CI 0.67–2.04), absolute reticulocyte count 100–175 (cumulative
mean frequency of events 0.94, 95% CI 0.51–1.75), absolute reticulocyte
count ,100 (cumulative mean frequency of events 0.36, 95% CI 0.15–
0.88)]. In both panels, the p value represents the differences among the
four groups. ARC, Absolute Reticulocyte Count.
doi:10.1371/journal.pone.0070794.g004
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